Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Dr Alfredo Addeo (University Hospital of Geneva, Geneva, Switzerland), Prof Nicolas Girard (Institut Curie, Paris, France), Dr Anna Minchom (Institute of Cancer Research, London, UK) and Prof Pascale Tomasini (Aix-Marseille University, Marseille, France) discuss the latest advances in EGFR-mutant non-small cell lung cancer (NSCLC).
The panel reviews newly presented clinical trial data, evolving treatment strategies, mechanisms of resistance, and innovations in drug delivery that can reshape clinical practice.
They discus emerging results from key studies presented at ESMO 2025, including OptiTROP-Lung04, FLAURA, MARIPOSA, PALOMA, and others.
Experts examine efficacy outcomes, safety profiles, CNS activity, and implications for first-line and sequential therapy selection.
They conclude by discussing advancements in drug delivery and future directions.
| FLAURA2: exploratory overall survival (OS) analysis in patients (pts) with poorer prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment (tx) for EGFR-mutated (EGFRm) advanced NSCLC | |
| Overall survival with amivantamab–lazertinib in EGFR-mutated advanced NSCLC | |
| NorthStar: A phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR-mutant non-small cell lung cancer (NSCLC) | |
| Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: results from the randomized, multi-center phase 3 OptiTROP-Lung04 study | |
| Subcutaneous (SC) amivantamab (ami) plus chemotherapy (chemo) in EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC) after disease progression on osimertinib (osi) | |
| Phase II study of firmonertinib in patients with previously treated advanced/metastatic non-small cell lung cancer (mNSCLC) with EGFR exon 20 insertion (ex20ins) mutations |
